Wearing a red ribbon, standing on the podium of the provincial science and technology innovation conference, from the provincial leadership to take over the red "Shandong Province Science and Technology Progress Award" certificate ...... June 22 at 9 a.m., in the province's vast number of science and technology workers witnessed, the Dia Pharmaceutical Group Research Center Director Miao Huaming as the city's only enterprise representative, the scene accepted the provincial party committee, the provincial government's scientific and technological innovation commendation.

The project of "key technology innovation and production system construction of industrialization of characteristic chemical drug raw materials and preparations", which was awarded the first prize of provincial scientific and technological progress in 2021, is a comprehensive scientific and technological achievement, which was accumulated by the scientific research team of Dijia Pharmaceutical for nearly six years.

"I was very excited at the moment when I accepted the honor on behalf of the enterprise. After listening to the sharing of the highest award winner and the speech of the provincial leaders, I felt that the responsibility was heavier. As a scientific researcher in the front line of the enterprise, we still need to impact towards a higher scientific and technological peak." After the meeting, Miao Huaming revealed his feelings at the scene to reporters for the first time.

The front-line scientific research of enterprises is a process of constantly surpassing themselves in the actual combat of the industry, and it is also a process of breaking through the technology of sticking neck one by one. "while producing, discovering problems, overcoming difficulties and developing technologies, it can be said that each of the eight innovative technologies in subdivided areas directly solves the pain points in the drug production process." Speaking of this award-winning technology, Miao Huaming is like a treasure: "For example, advanced biological enzyme catalysis technology solves the pollution caused by the original chemical synthesis; recycling technology maximizes waste utilization and forms a large cycle of the whole process of drug production; integrated online control technology greatly improves the quality level of drugs, and the impurity rate can be reduced to less than five ten thousandth ......" In this new stage of development that pursues green production and saves energy and reduces consumption, this innovation has undoubtedly opened the green door of traditional pharmaceutical companies, which is of great significance.

Behind everyone's invisibility, this province's "first prize" is not easy to win. Behind this is the company's consistent persistence in innovation and the silent adherence to quality and responsibility of a group of researchers.

Miao Huaming said that in the most critical years of project research and development, it is also an important period for the implementation of the national consistency evaluation superimposed drug centralized procurement policy. In the industry environment, the profit margin of enterprises is inevitably affected to a certain extent, but it has never reduced a penny of innovation and R & D investment. "The state's policy is to force enterprises to improve quality and control costs. To achieve these two points, innovation is the only way out." Miao Huaming said, "In the past two years, companies have continued to expand their investment in technological innovation, and each year they spend 0.1 billion yuan on technological innovation. With such support, what we can do is to study it seriously."

Scientific and technological innovation is a collaborative attack of funds and talents. There are 12 project teams that won the provincial first prize this time, including 6 doctors including Miao Huaming, many of whom have been rooted in this industry for more than ten years. Among them, many of them went out of school and directly entered the enterprise, because their professional counterparts chose Weihai, and because their career platform stayed in Weihai, changing from a "foreign talent" to an out-and-out Weihai native.

Walking out of the conference hall, a sentence mentioned at the meeting was always lingering in Miao Huaming's mind: "The key core technology is not to come, can not be bought, can not be asked for. This is also the original intention of our scientific research, to the small, to improve the quality of products, to the big, to make our domestic drugs more straight and more upright!"

There was no rush to tell each other, no first time to share the photos of the scene, in the face of honor, the way of "celebration" of this group of researchers was very low-key. On the same day, Miao Huaming did not rush back to Weihai, but went to the enterprise's research institute in Jinan for business docking. "Next, what we have to do is to continue to deepen, refine, and dig, and carry out meticulous research on key technologies, and make two or three of the key core technologies top in the industry, and strive to become a benchmark, which can be regarded as a contribution to the entire industry." Miao Huaming is in a hurry and has a firm goal.